00:00The commitment of Bristol was born for psoriasis about 10 years ago with the Deo Cravasitinib
00:10that we studied in great detail and that today we are happy to be able to announce the reimbursement
00:18for the treatment of adult patients with moderate and severe psoriasis and who are
00:24candidates for systemic therapy. In the field of immunology, however, we are proud
00:31to be able to claim the fact of being pioneers in this field and of having studied the immune system
00:37very thoroughly , so much so that we have been able to develop molecules both for
00:42the treatment of autoimmune diseases where it is important to modulate and try to reduce
00:47the immune response and in the treatment of oncological and hematological pathologies
00:52where it is important to stimulate the activity of the immune system. Deo Cravasitinib is an
00:58oral therapy that acts on a protein on which none of the therapies, even numerous,
01:05that are available to patients, act and we are talking in particular about the protein TIK2 which
01:11has an important role in regulating the immune system. The data confirm the fact that it is a
01:20very active molecule, so much so that we have already given to four years that show both the
01:26duration of the important response and the profile of safety which has shown to be a
01:35very well tolerated molecule. In the field of psoriasis, however, it is very important for patients to
01:40have an additional therapeutic opportunity as psoriasis is cured but unfortunately it is not
01:47cured, so they are patients who have a very long history of disease and it is important to be able to
01:54have new opportunities to cure and try to manage the symptoms for as long as possible and
02:03have new opportunities when previous therapies fail to maintain the response.
Comments